Payment overview · 2025
General Payments
$563.84
26 reported records · 11 companies
Healthcare provider profile · identity verified
G. Michael Lopez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NM · NPI 1003973397
Verified facts
What the public records show
CMS Open Payments records show G. Michael Lopez, M.D. received $563.84 in general payments during 2025 across 26 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $173.48 | 30.8% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $81.99 | 14.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.82 | 11.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.27 | 10.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.26 | 7.1% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $40.05 | 7.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.37 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.71 | 4.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.08 | 4.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.89 | 3.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.92 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $563.84 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $173.48 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $81.99 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.26 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $40.05 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 185 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 342 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
342 | 74 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
115 | 22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 686 | 199 |
| Simvastatin | Simvastatin | 565 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 115 |
| Alprazolam | Alprazolam | 377 | 44 |
| Omeprazole | Omeprazole | 363 | 111 |
| Ozempic | Semaglutide | 342 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 334 | 99 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 325 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 81 |
| Lisinopril | Lisinopril | 295 | 85 |
| Tramadol Hcl | Tramadol Hcl | 279 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 66 |
| Gabapentin | Gabapentin | 228 | 64 |
| Trazodone Hcl | Trazodone Hcl | 202 | 45 |
| Eliquis | Apixaban | 200 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 84 |
| Mirtazapine | Mirtazapine | 186 | 45 |
| Jardiance | Empagliflozin | 185 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 56 |
| Alendronate Sodium | Alendronate Sodium | 169 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 50 |
| Losartan Potassium | Losartan Potassium | 157 | 47 |
| Lorazepam | Lorazepam | 149 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 141 | 40 |
| Azithromycin | Azithromycin | 140 | 100 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 40 |
| Metformin Hcl Er | Metformin Hcl | 135 | 39 |
| Synthroid | Levothyroxine Sodium | 132 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 47 |
| Ondansetron Odt | Ondansetron | 123 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 31 |
| Xarelto | Rivaroxaban | 117 | 25 |
| Sertraline Hcl | Sertraline Hcl | 116 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 29 |
| Rybelsus | Semaglutide | 115 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 31 |
| Furosemide | Furosemide | 103 | 39 |
| Spironolactone | Spironolactone | 103 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 102 | 33 |
| Trulicity | Dulaglutide | 100 | 19 |
| Farxiga | Dapagliflozin Propanediol | 98 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 97 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 96 | 26 |
| Finasteride | Finasteride | 95 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 94 | 26 |
| Repatha Sureclick | Evolocumab | 94 | 16 |
| Carvedilol | Carvedilol | 93 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 92 | 28 |
| Entresto | Sacubitril/Valsartan | 90 | 18 |
| Prednisone | Prednisone | 89 | 37 |
| Potassium Chloride | Potassium Chloride | 88 | 28 |
| Myrbetriq | Mirabegron | 87 | 23 |
| Clobetasol Propionate | Clobetasol Propionate | 77 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 24 |
| Allopurinol | Allopurinol | 74 | 19 |
| Donepezil Hcl | Donepezil Hcl | 74 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Ibuprofen | Ibuprofen | 65 | 21 |
| Famotidine | Famotidine | 64 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 31 |
| Ezetimibe | Ezetimibe | 62 | 19 |
| Mounjaro | Tirzepatide | 61 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 60 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 14 |
| Carisoprodol | Carisoprodol | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 15 |
| Bupropion Xl | Bupropion Hcl | 50 | 11 |
| Levetiracetam | Levetiracetam | 50 | 11 |
| Pregabalin | Pregabalin | 48 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 16 |
| Colchicine | Colchicine | 46 | 11 |
| Linzess | Linaclotide | 46 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 16 |
| Diazepam | Diazepam | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 11 |
| Methotrexate | Methotrexate Sodium | 42 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 41 | 17 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 31 |
| Meclizine Hcl | Meclizine Hcl | 39 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 31 |
| Indomethacin | Indomethacin | 35 | 13 |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 24 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 28 |
| Temazepam | Temazepam | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Lactulose | Lactulose | 31 | 17 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 21 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 30 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 29 | 16 |
| Felodipine Er | Felodipine | 29 | 11 |
| Baclofen | Baclofen | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 24 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | 11 |
| Naproxen | Naproxen | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Fluocinonide | Fluocinonide | 23 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Qulipta | Atogepant | 18 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | 11 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Tretinoin | Tretinoin | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Meperidine Hcl | Meperidine Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $563.84 · 26 records | Bayer Healthcare Pharmaceuticals Inc. | BREZTRI, CAPVAXIVE, INGREZZA, JARDIANCE, Kerendia, MOUNJARO, NUCALA, Ozempic, REXULTI, SUBLOCADE, VERQUVO, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error